Skip to main content
    M

    Molecular Partners AG ADR (MOLN)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $2.67
    -0.27 (-9.18%)

    Market Cap: $112.71M

    Last updated: Nov 17, 2026 at 10:12 AM ET

    Molecular Partners AG ADR (MOLN) Financials: Revenue, Profit and Cash Flow

    Updated Oct 29, 2026. Financial statements from company filings, amounts in CHF.

    Molecular Partners AG ADR reported revenue of CHF 0 for the fiscal year ended Dec 31, 2025, down 100.0% from the year before. That year, net income was CHF -61.65M, operating cash flow was CHF -51.26M and free cash flow was CHF -51.97M. The quarter ended Sep 30, 2026 had revenue of CHF 0 and net income of CHF -11.71M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of CHF 58.12M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 20250-100.0%N/AN/AN/A
    Dec 20244.97M-29.4%-855.8%-1231.7%-1087.4%
    Dec 20237.04M-96.3%-579.8%-868.3%-880.7%
    Dec 2022189.56M+1931.7%100.0%61.5%62.2%
    Dec 20219.33M-0.1%-497.2%-679.7%-683.7%
    Dec 20209.34M-54.2%-500.1%-624.2%-671.7%
    Dec 201920.38M+96.8%-113.4%-179.9%-178.0%
    Dec 201810.36M-48.3%-50.7%-361.3%-357.7%
    Dec 201720.02M-13.1%11.0%-129.1%-127.0%
    Dec 201623.04MN/A36.8%-84.6%-80.8%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue04.97M7.04M189.56M9.33M9.34M20.38M10.36M20.02M23.04M
    Cost of revenue2.05M47.50M47.84M-44.00K55.72M56.08M43.50M15.60M17.82M14.57M
    Gross profit-2.05M-42.53M-40.81M189.60M-46.39M-46.73M-23.11M-5.25M2.19M8.47M
    Research and development40.19M48.60M48.78M50.75M55.72M56.08M43.50M38.20M37.45M35.19M
    Operating income-58.12M-61.22M-61.11M116.61M-63.42M-58.33M-36.66M-37.41M-25.84M-19.49M
    Net income-61.65M-54.04M-61.98M117.85M-63.78M-62.76M-36.29M-37.04M-25.43M-18.61M
    EBITDAN/A-51.65M-59.52M120.85M-60.66MN/A-33.70M-36.11M-24.70M-17.52M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue00000000681.00K1.55M2.74M1.03M
    Gross profit-12.06M-482.10K-9.45M-641.87K-658.57K-668.78K-614.03K-9.45M-10.18M-11.54M-11.37M-10.88M
    Operating income-12.06M-13.54M-13.44M-15.85M-14.91M-17.32M-17.96M-14.79M-14.59M-15.98M-15.86M-16.65M
    Net income-11.71M-13.51M-13.14M-15.83M-14.79M-20.40M-18.66M-11.23M-16.40M-15.08M-11.32M-19.78M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of CHF 1.21M by 81.45M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets102.11M158.53M198.35M262.26M172.67M187.55M104.94M155.16M144.42M184.10M
    Current assets96.88M154.28M192.46M254.75M164.19M177.81M99.92M153.32M142.53M181.56M
    Cash and equivalents82.65M63.87M67.31M87.95M71.81M133.72M75.71M98.96M131.32M149.74M
    Total liabilities21.77M16.89M21.92M27.09M65.38M80.33M50.80M63.45M27.69M48.30M
    Short-term debt1.21M1.22M1.21M1.20M1.19M1.18M1.27MN/AN/AN/A
    Shareholder equity80.33M141.64M176.43M235.17M107.29M107.22M54.14M91.70M116.73M135.79M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets64.52M75.43M87.40M102.11M112.15M124.25M141.10M158.53M154.21M170.62M185.60M198.35M
    Total liabilities13.85M17.09M19.15M21.77M16.62M17.59M12.90M16.89M15.43M15.05M17.06M21.92M
    Cash and equivalents57.49M67.69M64.25M82.65M82.36M81.97M81.37M63.87M65.75M65.69M68.34M67.31M
    Shareholder equity50.66M58.34M68.25M80.33M95.53M106.66M128.19M141.64M138.78M155.57M168.54M176.43M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-51.26M-59.25M-59.01M118.57M-90.95M-28.98M-1.19M-42.47M-40.02M-35.38M
    Capital expenditures714.00K723.00K575.00K1.18M1.31M1.68M1.86M867.00K500.00K1.10M
    Free cash flow-51.97M-59.97M-59.58M117.39M-92.26M-30.67M-3.05M-43.34M-40.52M-36.48M
    Dividends paidN/AN/AN/A250.00KN/AN/AN/AN/AN/AN/A
    Investing cash flow72.55M40.49M44.64M-101.12M-22.24M-21.75M-19.84M9.61M20.86M-11.25M
    Financing cash flow-1.15M14.43M-1.17M-1.57M50.58M113.20M-227.00K392.00K799.00K395.00K
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-10.51M-10.81M-14.47M-13.45M-12.78M-13.10M-17.08M-13.20M-13.28M-15.72M-17.05M-15.99M
    Capital expendituresN/A20.46K0174.42K63.13K96.00K448.00K137.00K258.00K197.00K131.00K310.00K
    Free cash flowN/A-10.83M-14.47M-13.63M-12.84M-13.20M-17.53M-13.33M-13.54M-15.92M-17.18M-16.30M
    Last 12 quarters

    Frequently Asked Questions About MOLN

    What is Molecular Partners AG ADR's annual revenue?

    Molecular Partners AG ADR reported revenue of CHF 0 for the fiscal year ended Dec 31, 2025.

    How fast is Molecular Partners AG ADR's revenue growing?

    Revenue was down 100.0% for the fiscal year ended Dec 31, 2025 compared with the year before.

    Is Molecular Partners AG ADR profitable?

    No. Molecular Partners AG ADR reported net income of CHF -61.65M for the fiscal year ended Dec 31, 2025.

    How much free cash flow does MOLN generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of CHF -51.26M minus capital expenditures of CHF 714.00K produced free cash flow of CHF -51.97M.

    How much debt does Molecular Partners AG ADR have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of CHF 1.21M and cash and equivalents of CHF 82.65M.